Carcinoma, Intraductal, Noninfiltrating

The supplied grounding does not support a specific cause or aetiology for this disease. It is described as a heterogeneous neoplastic lesion, but no single causal factor is established in the provided material.

The disease consists of malignant epithelial proliferation that remains within ducts or lobules without stromal invasion. The literature also frames DCIS as a pre-invasive breast carcinoma that may progress to invasive ductal carcinoma, with progression linked to molecular changes in tumor cells and alterations in the tumor microenvironment. The supplied material additionally notes interest in signaling pathways, genetics, and metabolism, but does not provide specific mechanisms beyond these broad themes.

The supplied grounding does not identify specific risk factors for developing this disease. It does indicate that some DCIS lesions may progress to invasive breast cancer, but that is a progression feature rather than a risk factor for onset.

Management is described at the level of workup, primary treatment, risk reduction strategies, and surveillance for DCIS. The goal of treatment is to prevent development of invasive breast cancer, and the literature also supports estrogen receptor testing to identify patients who may benefit from endocrine therapy. No specific drug regimens or procedural details are provided in the grounding.